Mind Medicine (MindMed) Inc. (MMED.NE)
- Previous Close
13.61 - Open
12.50 - Bid 14.60 x --
- Ask 14.95 x --
- Day's Range
11.60 - 15.07 - 52 Week Range
3.30 - 16.40 - Volume
81,492 - Avg. Volume
72,598 - Market Cap (intraday)
1.05B - Beta (5Y Monthly) 2.53
- PE Ratio (TTM)
-- - EPS (TTM)
-3.31 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
www.mindmed.co57
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: MMED.NE
Compare To: MMED.NE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MMED.NE
Valuation Measures
Market Cap
1.05B
Enterprise Value
934.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-10.30
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.84%
Return on Equity (ttm)
-83.59%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-95.73M
Diluted EPS (ttm)
-3.31
Balance Sheet and Cash Flow
Total Cash (mrq)
99.7M
Total Debt/Equity (mrq)
18.08%
Levered Free Cash Flow (ttm)
-25.91M
Research Analysis: MMED.NE
Company Insights: MMED.NE
MMED.NE does not have Company Insights